Seed · Healthtech
Acurion closes $4.3m seed led by TK & Partners
The oversubscribed round exceeds its $4m target and backs clinical validation and commercialisation preparation.
Capital for clinical and regulatory milestones
TK & Partners led Acurion’s $4.3m seed, exceeding a $4m target. Participants included Mesa Verde Venture Partners, the National Foundation for Cancer Research, the Asian Fund for Cancer Research and Bootstrap Ventures.
The financing supports clinical validation, platform development, regulatory preparation and commercialisation. CEO Rick Fultz said the priority was execution of clinical and regulatory milestones, with additional collaborations and progress expected later. The announcement did not establish a completed market approval.
Funding history
Seed · This round$4.3M